Ready-to-use products by Par Pharmaceutical, Inc.

Significant operational improvement
is possible

TruDelivery® ready-to-use (RTU) products are easy
to stock, store, and deliver

Designed for today’s hospital pharmacies, pharmacists, and healthcare providers, TruDelivery® RTU products may contribute to greater workflow efficiency and save time.1 The entire portfolio is:

  • FDA approved2-6
  • Prepared by the manufacturer in compliance with exacting governmental standards7-13
  • Compatible with most automated dispensing machines

Most hospital pharmacy buyers can purchase TruDelivery® RTU products with their routine daily wholesale orders. These TruDelivery® RTU products are already available through your health system’s full-line wholesaler and on your group purchasing organization (GPO) contract.

Advantages for hospital pharmacies include:

  • Convenient, RTU delivery2-6
  • Reduced risk of medication error14
  • Extended dating compared with 503B compounded and in-house compounded products15-20*
  • Optimized inventory management1
  • Supportive of efforts to reduce waste21
  • Lowered risk for contamination1,22-24
  • Reduced cost and time associated with compounding: vial, bag, diluent, pharmacy prep time25-27
  • Focus on compounding products without an RTU alternative

TruDelivery® RTU product portfolio

*

For Category 3 controlled sterile preparations (CSP), the maximum beyond-use date (BUD) is 90 days at controlled room temperature (CRT), 120 days in refrigerator, and 180 days in freezer20 versus shelf life of 2 years at CRT for Ephedrine, PREVDUO®, and Dexmedetomidine15-17; 12 months at CRT and 2 years in refrigerator for Vasostrict®19; 72 hours at CRT and 18 months in refrigerator for Bivalirudin.5,18

References: 1. Fanikos J, Burger M, Canada T, et al. An assessment of currently available i.v. push medication delivery systems. Am J Health-Syst Pharm. 2017;74(9):e230-235. 2. Vasostrict®. Prescribing Information. Par Pharmaceutical, Inc. 3. Ephedrine Sulfate Injection. Prescribing Information. Par Pharmaceutical, Inc. 4. Dexmedetomidine Hydrochloride Injection. Prescribing Information. Par Pharmaceutical, Inc.
5. Bivalirudin Injection. Prescribing Information. Par Pharmaceutical, Inc. 6. PREVDUO®. Prescribing Information. Par Pharmaceutical, Inc. 7. U.S. Food & Drug Administration. New Drug Approval for Ephedrine Sulfate Injection: NDA 213994. October 16, 2020. Accessed November 8, 2023. 8. U.S. Food & Drug Administration. New Drug Approval for PREVDUO: NDA 216903. February 23, 2023. Accessed November 8, 2023. 9. U.S. Food & Drug Administration. Abbreviated New Drug Approval for Dexmedetomidine Hydrochloride: ANDA 208532. August 18, 2014. Accessed November 8, 2023. 10. U.S. Food & Drug Administration. Supplemental Abbreviated New Drug Approval for Dexmedetomidine Hydrochloride: ANDA 208266/S-001. October 19, 2020. Accessed November 8, 2023. 11. U.S. Food & Drug Administration. Supplemental New Drug Approval for VASOSTRICT, 40 and 60 units: NDA 204485/S-013. April 15, 2020. Accessed November 8, 2023. 12. U.S. Food & Drug Administration. Supplemental New Drug Approval for VASOSTRICT, 20 units: NDA 204485/S-020. April 21, 2021. Accessed November 8, 2023. 13. U.S. Food & Drug Administration. New Drug Approval for ANGIOMAX RTU (bivalirudin) Injection: NDA 211215. July 25, 2019. Accessed November 8, 2023. 14. American Society of Health-System Pharmacists. ASHP guidelines on preventing medication errors in hospitals. Am J Health-Syst Pharm. 2018;75(19):1493-1517. 15. Data on file. PSP-PRVD-01. Par Pharmaceutical, Inc.; July 20, 2023. 16. Data on file. DOF-EH-01. Par Pharmaceutical, Inc.; July 31, 2023. 17. Data on file. DOF-DX-01. Par Pharmaceutical, Inc.; July 27, 2023. 18. Healthcare Distribution Alliance. Standard pharmaceutical product and medical device information: Bivalirudin Injection. July 10, 2023. 19. Data on file. DOF-VS-02. Par Pharmaceutical, Inc.; September 21, 2023. 20. The United States Pharmacopeial Convention. USP compounding standards and beyond-use dates. https://go.usp.org/2022_Revisions_795_797. Accessed November 8, 2023. 21. American Society of Health-System Pharmacists. ASHP guidelines on medication cost management strategies for hospitals and health systems. Am J Health-Syst Pharm. 2008;65:1368-1384. 22. Institute for Safe Medication Practices. ISMP safe practice guidelines for adult IV push medications. https://www.ismp.org/sites/default/files/attachments/2017-11/ISMP97-Guidelines-071415-3.%20FINAL.pdf. Accessed November 8, 2023. 23. Hertig JB, Degnan DD, Scott CR, Lenz JR, Li X, Anderson CM. A comparison of error rates between intravenous push methods: a prospective, multisite, observational study. J Patient Saf. 2018;14(1):60-65. 24. U.S. Food & Drug Administration, Department of Health and Human Services, Center for Drug Evaluation and Research. Safety considerations for product design to minimize medication errors: guidance for industry. https://www.fda.gov/media/84903/download. Revised April 2016. Accessed November 8, 2023. 25. van der Linden P, Douchamps J, Schmitt C, Forget D. Ready-to-use injection preparations versus conventional reconstituted admixtures: economic evaluation in a real-life setting. Pharmacoeconomics. 2002;20(8):529-536. 26. Myers E, Rosenberg S. Prefilled syringe vaccine doses: an emerging option in the retail-based clinic setting. Pharmacy Times Oncology Edition. 2015;2(1).
27. Pereira CC, Bishai D. Vaccine presentation in the USA: economics of prefilled syringes versus multidose vials for influenza vaccination. Expert Rev Vaccines. 2010;9(11):1343-1349. Erratum in: Expert Rev Vaccines. 2011;10(1):132.

© 2024 Par Pharmaceutical, Inc.
All rights reserved.

PSP-MULTI-05012/February 2024  parpharm.com